Metronomic chemotherapy: changing the paradigm that more is better

The introduction of the “maximum tolerated dose” in usual treatment protocols (and its concomitant overt toxicity) made necessary the imposition of rest periods between cycles of therapy—a practice that not only involves re-growth of tumour cells, but also growth of selected clones resistant to the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scharovsky, O. Graciela, Mainetti, Leandro Ernesto, Rozados, Viviana R.
Formato:	article artículo publishedVersion
Lenguaje:	Inglés
Publicado:	Multimed Inc. 2012
Materias:	Metronomic chemotherapy Angiogenesis Optimal biologic dose OBD Circulating endothelial cells CECs Circulating endothelial progenitors CEPs
Acceso en línea:	http://hdl.handle.net/2133/2008 http://hdl.handle.net/2133/2008
Aporte de:	Repositorio Hipermedial de la Universidad Nacional de Rosario (UNR) de Universidad Nacional de Rosario

id	I15-R121-2133-2008
record_format	dspace
institution	Universidad Nacional de Rosario
institution_str	I-15
repository_str	R-121
collection	Repositorio Hipermedial de la Universidad Nacional de Rosario (UNR)
language	Inglés
orig_language_str_mv	en
topic	Metronomic chemotherapy Angiogenesis Optimal biologic dose OBD Circulating endothelial cells CECs Circulating endothelial progenitors CEPs
spellingShingle	Metronomic chemotherapy Angiogenesis Optimal biologic dose OBD Circulating endothelial cells CECs Circulating endothelial progenitors CEPs Scharovsky, O. Graciela Mainetti, Leandro Ernesto Rozados, Viviana R. Metronomic chemotherapy: changing the paradigm that more is better
topic_facet	Metronomic chemotherapy Angiogenesis Optimal biologic dose OBD Circulating endothelial cells CECs Circulating endothelial progenitors CEPs
description	The introduction of the “maximum tolerated dose” in usual treatment protocols (and its concomitant overt toxicity) made necessary the imposition of rest periods between cycles of therapy—a practice that not only involves re-growth of tumour cells, but also growth of selected clones resistant to the therapy. To avoid the problems caused by traditional chemotherapeutic regimens, a new modality of drug administration called “metronomic chemotherapy” has been proposed. This name makes reference to the chronic, equally spaced administration of (generally) low doses of various chemotherapeutic drugs without extended rest periods. The novelty of this treatment modality lies not only in its antitumour efficacy with very low toxicity, but also in a cell target switch, now aiming at tumour endothelial cells. The knowledge acquired in the experimental field of metronomic chemotherapy, plus the increasing experience that is being obtained in the clinical setting, will help to lead a change in the design of therapeutic protocols against cancer.
format	article artículo publishedVersion
author	Scharovsky, O. Graciela Mainetti, Leandro Ernesto Rozados, Viviana R.
author_facet	Scharovsky, O. Graciela Mainetti, Leandro Ernesto Rozados, Viviana R.
author_sort	Scharovsky, O. Graciela
title	Metronomic chemotherapy: changing the paradigm that more is better
title_short	Metronomic chemotherapy: changing the paradigm that more is better
title_full	Metronomic chemotherapy: changing the paradigm that more is better
title_fullStr	Metronomic chemotherapy: changing the paradigm that more is better
title_full_unstemmed	Metronomic chemotherapy: changing the paradigm that more is better
title_sort	metronomic chemotherapy: changing the paradigm that more is better
publisher	Multimed Inc.
publishDate	2012
url	http://hdl.handle.net/2133/2008 http://hdl.handle.net/2133/2008
work_keys_str_mv	AT scharovskyograciela metronomicchemotherapychangingtheparadigmthatmoreisbetter AT mainettileandroernesto metronomicchemotherapychangingtheparadigmthatmoreisbetter AT rozadosvivianar metronomicchemotherapychangingtheparadigmthatmoreisbetter
bdutipo_str	Repositorios
_version_	1764820411280785410

Metronomic chemotherapy: changing the paradigm that more is better

Ejemplares similares